ALK-Abelló

Major Shareholding Notification • Oct 12, 2017

Copenhagen, 2017-10-12 22:43 CEST (GLOBE NEWSWIRE) --

Pursuant to section 29 of the Danish Securities Trading Act, ALK (ALKB:DC /
OMX: ALK B / AKABY / AKBLF) has received notification from Jupiter Asset
Management Ltd., that Jupiter Asset Management Ltd. has reduced its ownership
in ALK to below 5% of the share capital.

The notifications from Jupiter Asset Management Ltd. are attached to this
company release.

                             ALK-Abelló A/S

For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy
prevention, diagnosis and treatment. ALK is a world leader in allergy
immunotherapy – a treatment of the underlying cause of allergy. The company has
approximately 2,300 employees, with subsidiaries, production facilities and
distributors worldwide. ALK has entered into partnership agreements with Torii,
Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets
in Japan, Russia, and South-East Asia, and Australia and New Zealand,
respectively. The company is headquartered in Hørsholm, Denmark, and listed on
Nasdaq Copenhagen. Find more information at www.alk.net.